Targeting Epstein-Barr Virus Infections in Multiple Sclerosis Management
Overview
Epstein-Barr virus (EBV) is strongly implicated in the pathogenesis of multiple sclerosis (MS), potentially through mechanisms such as molecular mimicry and active latent-lytic infection cycles. Emerging therapeutic strategies targeting EBV include antiviral agents and immunotherapies, which may modify MS disease activity and progression.
Background
EBV infection is nearly universal in MS patients and is considered necessary but not sufficient for MS development. The virus may contribute to MS via immune dysregulation, molecular mimicry, or direct viral activity within the central nervous system. Current MS treatments may exert effects by targeting EBV-infected B cells, and novel therapies aim to directly inhibit EBV or boost EBV-specific immune responses. Understanding EBV's role in MS is critical for developing targeted preventive and therapeutic interventions.
Data Highlights
EBV-negative individuals have an almost zero risk of developing MS, and seroconversion to EBV positivity precedes MS onset. Molecular mimicry between EBV antigens and CNS autoantigens has been demonstrated, though immune tolerance mechanisms limit autoreactivity. B-cell depleting therapies show anti-EBV activity, and innovative immunotherapies such as EBV-specific cytotoxic T cells and CAR T cells are under investigation.
Key Findings
EBV infection is strongly associated with MS and likely plays a causal role in its pathogenesis.
Molecular mimicry between EBV proteins and CNS autoantigens may trigger autoimmune responses in MS.
Active EBV latent-lytic infection cycles may drive ongoing MS disease activity.
Anti-EBV strategies include CNS-penetrant antivirals and immunotherapies such as EBV-specific cytotoxic T cells and therapeutic vaccines.
Licensed MS therapies, including B-cell depleting agents, may exert part of their effect by targeting EBV-infected cells.
Innovative clinical trial designs are needed to evaluate anti-EBV treatments for MS prevention and management.
Clinical Implications
Clinicians should consider the role of EBV in MS pathogenesis when selecting therapeutic strategies, especially those targeting B cells. Emerging antiviral and immunotherapeutic approaches targeting EBV offer promising avenues for modifying disease activity. Future clinical trials are essential to establish the efficacy and safety of these EBV-targeted treatments in MS.
Conclusion
EBV plays a critical role in MS development and progression, making it a compelling target for novel therapeutic interventions. Integrating antiviral and immunotherapeutic strategies against EBV could transform MS prevention and treatment paradigms.
References
Epstein-Barr Virus and Multiple Sclerosis Research, 2024 -- Targeting Latent and Lytic Infections of Epstein-Barr Virus in the Context of Multiple Sclerosis
